


This example is for a patient who has NCCN high/very high-risk disease. Active surveillance insights are only reported for those who have NCCN very low-, low-, and favorable intermediate-risk disease, abiraterone insights are only reported for those who have NCCN high- and very high-risk disease, and ST-ADT biomarker results are only reported for those who have NCCN intermediate-risk disease.



Name: John Doe
Date of Birth: 08/08/1964

ArteraAI Prostate Test Report

PATIENT DETAILS

PATIENT
Name: John Doe
Date of Birth: 08/08/1964
Condition: Prostate Cancer

PHYSICIAN
Name: Adam Smith, MD
Clinic Name: Artera Hospital

CLINICAL AND PATHOLOGY
Clinical Tumor Stage: T3a
Pre-biopsy PSA: 23.2 ng/mL
Gleason Score: 8 (4+4)
Patient Age at Order Date: 71
NCCN Risk: Very High

ORDER
Order Date: 07/01/2023
Test Run Date: 07/04/2023
Artera ID: AM-4Y-VRD-005K
Accession Number: ART-25-XXXXX


PROGNOSTIC RISK

HIGH

ArteraAI Prognostic Raw Score=0.55


10-YEAR RISK OF DISTANT METASTASIS

(With standard of care treatment)



THIS PATIENT
13% RISK

COMPARISON OF THIS PATIENT TO THOSE IN SAME NCCN RISK GROUP



THIS PATIENT
75th percentile

This patient has an estimated 10-year risk of metastasis that is **higher than 75%** of patients in the same NCCN high/very high risk group.


10-YEAR RISK OF PROSTATE CANCER SPECIFIC MORTALITY

(With standard of care treatment)

9.0%


95% CI: 8.0%-10.0%

HIGH RISK INSIGHTS



More Likely to Benefit from Abiraterone

On average, patients with this result had **improved MFS and PCSM risk reduction** with the addition of abiraterone to long-term androgen deprivation therapy ± RT.


Reviewed by Laboratory Director
Joshua B. Kish, MD

07/07/2025 12:00PM
Review Date and Time (EST)

The ArteraAI Prostate Test results are provided to support risk-based decisions within the recommended guidelines, taking into consideration all other patient factors.

[By signing this I am confirming adequate quality of the material received, image reviewed and presence of cancer, unless otherwise noted in this report.]

A Prognostic Risk: The ArteraAI prognostic risk group can explain how aggressive the patient's prostate cancer is. The 10-year risk of distant metastasis is reported as a continuous variable with low-, intermediate-, and high-risk categories.


B Additional Prognostic Endpoints: In addition to the 10-year risk of distant metastasis, 10-year risk of prostate cancer-specific mortality is also reported. This can help provide more information to support optimized decision-making.

C Comparison With National Comprehensive Cancer Network (NCCN) Risk Group: There is variability among patients within NCCN risk groups. A visualization is provided to show how the risk of metastasis, based on the ArteraAI risk score, compares to other patients with NCCN high/very high-risk disease.


D High Risk Insight - Adjunctive Abiraterone Therapy Benefit: For men with NCCN high- and very high-risk disease, a therapeutic signal for abiraterone adjunctive therapy is provided. Based on a prognostic score cutoff, patients above the cutoff are more likely to benefit from abiraterone added to LT-ADT +/- radiation therapy, whereas patients below the cutoff are less likely to benefit. In an analysis of 1336 high-risk non-metastatic patients, 25% (334) of patients were found to likely benefit from abiraterone adjunctive therapy and 75% (1002) of patients were found to not likely to benefit from abiraterone adjunctive therapy.

This example is for a patient who has NCCN high/very high-risk disease. Active surveillance insights are only reported for those who have NCCN very low-, low-, and favorable intermediate-risk disease, abiraterone insights are only reported for those who have NCCN high- and very high-risk disease, and ST-ADT biomarker results are only reported for those who have NCCN intermediate-risk disease.

E



F



E LT-ADT Pooled Cohort Analysis: This is a pooled cohort analysis of the estimated 10-year risk of distant metastasis (DM) of 1016 patients with NCCN high- and very-high disease treated with 24-28 months of LT-ADT +/- radiation therapy. Patients with an MMAI High score had a 10-year risk of DM of 26.8%, whereas patients with an MMAI Low or Intermediate score had a 10-year risk of DM of 7.0%.

F Data Supporting High Risk Insight Interpretation: In a clinical study, NCCN high- and very-high risk patients who were above the prognostic score cutoff had a significantly different rate of metastasis-free survival (MFS) rate when adding abiraterone therapy to LT-ADT to radiation therapy; patients who were below the prognostic score cutoff had little to no difference in the rate of MFS. The accompanying Kaplan-Meier (K-M) curve shows metastasis-free survival over time. The K-M curve highlighted by the blue box represents the clinical study data supporting the clinical interpretation on page 1 of the report.